We believe that conventional manufacturing tools and processes are not suited to deliver on the promise of today’s most advanced therapeutics. The pace of advancement in biological sciences and medicine requires innovation in the supporting ecosystem in order to translate breakthroughs into therapies that reach patients.

Our portfolio companies are advancing the science and art of bioprocessing to help bring advanced therapies to patients more quickly, safely, and efficiently.

  • We look for companies with differentiated technology that addresses a large and un- or under-met need in the market for advanced therapy development and manufacturing. We invest in pre-revenue stage businesses, however we look for opportunities where a majority of the technical risk has been retired.

  • We typically invest between $10 and 100M of equity in both majority controlling and minority non-controlling deals. We target founder-owned businesses and take a flexible approach to deal structuring to help achieve the particular goals of selling shareholders, management and other key stakeholders.

  • We look to leverage our team’s extensive industry knowledge to add value through an active investment relationship with our companies. We work collaboratively with management to shape the trajectory of a business following our investment.